Could HIV and age weaken vaccine protection? study investigates

NCT ID NCT03729778

Ongoing Knowledge-focused Sponsor: VA Eastern Colorado Health Care System Source: ClinicalTrials.gov ↗

First seen Jun 30, 2026 · Last updated Jul 30, 2026 · Updated 3 times

Summary

This study looks at how HIV infection and aging impact the body's response to the Prevnar 13 vaccine, which protects against pneumococcal bacteria. Researchers will measure antibody levels in the lungs, nasal passages, and blood of participants aged 21-45 or 55-75, comparing those with and without HIV. The goal is to understand why these groups face higher risks of serious infections and whether their immune systems respond differently to vaccination.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Prevnar 13 vaccine
What this could lead to: If successful, this could help tailor vaccination strategies for people with HIV and older adults, potentially reducing their risk of serious infections.
What could go wrong: This is an early-phase study with a small sample size, so results may not apply broadly. The vaccine's effectiveness in these groups remains uncertain.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HIV INFECTIONS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

AIDS HIV infectious disease pneumococcal infection

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HIV INFECTIONS HIV-1-INFECTION HIV/AIDS HUMAN IMMUNODEFICIENCY VIRUS

Contacts and locations

Locations

Rocky Mountain Regional VA Medical Center

Aurora, Colorado, 80045, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.